Commentary Health Investor Contribution

Scrubbing in together: Surgical robots and the future of the operating room

Kavitha Ravikumar •

• 22nd January 2025

The lights illuminate the sterile operating room, directing attention to the anesthetized form. Equipment and screens hum quietly as the robotic system waits, its metallic arms poised high. As the surgeon begins the procedure, a three dimensional model of the patient’s spine appears on the monitor, showcasing the surgical plan and intricate details of the vertebrae. Guided by advanced algorithms and real-time imaging, the robot-arm supervised by the surgeon, starts moving slowly towards the patient…

When you think of robotics, you might think of automated metallic factories, looping conveyor belts, trundling delivery robots or you might even picture nippy robotic pets gamboling by the roadside. Moving robotic arms performing surgical procedures is normally not the first thing that comes to mind.

The field of surgery has undergone a revolution with the integration of advanced technologies such as optoelectronics, robotics, and digital systems. This convergence has led to the development of minimally invasive (MI) surgery, which uses specialised instruments inserted through tiny incisions¹. Compared to traditional open surgery, MI techniques reduce blood loss, speed up healing, and improve recovery outcomes.

Robot-assisted surgery

Robot-assisted surgery (RAS), is a form of minimally invasive surgery that leverages robotic systems to perform complex procedures with heightened precision. Robotic technology in orthopedics was incorporated as far back as 1992, with the ROBODOC, for total hip replacement surgery².

Robotic systems can enable greater precision, overcoming human limitations like hand tremors or fatigue, and providing better access to challenging anatomical areas. Patients benefit from shorter hospital stays, reduced psychological stress, and lower radiation exposure through advanced navigation technologies³. However, challenges such as high equipment costs, extensive training requirements and occasional technical glitches remain.

Spinal applications

Now picture this, a cage like structure that grows and changes over time and is a conduit for over one million electrical messages per day.

The human spine is a complex structure and contains 120 muscles, around 220 ligaments, and 100 joints⁴. In fact people can be taller by 0.5 to 1.5 cm upon waking in the morning and become shorter over the day due to spinal compression⁵.

Using minimally invasive techniques and laparoscopes allows the surgeon to separate the muscles surrounding the spine with small incisions rather than cutting through them. When using manual laparoscopic instruments, surgeons carry out opposing movements within tiny incisions, often leaning, stooping or stretched out at awkward angles leading to fatigue, strain and injury.

Robotic assistance enhances these procedures by translating surgeons' hand movements into precise actions, smoothing tremors, and allowing for finer manipulations. Advanced imaging systems, including CT and MRI scans, help create detailed 3D models of the spine, enabling surgeons to pre-plan procedures and guide robotic arms during surgery. This approach minimizes damage to nearby nerves, blood vessels, and organs, making it particularly effective for complex surgeries like spinal fusions or instrumentation placement⁶.

Globus Medical

A recent entrant in the WHEB portfolio is Globus Medical, a leader in innovative spinal surgery systems. The company specialises in spinal implant systems, scoliosis correction tools, disc replacement technologies and advanced material technologies. Its flagship product, ExcelsiusGPS™, integrates robotics and navigation technologies to enhance surgical accuracy. This system allows surgeons to customise procedures based on each patient’s anatomy, reducing operative time and improving safety.

By 2021, over 20,000 spinal procedures had been performed using the ExcelsiusGPS™ system⁷. In the UK, the NHS and Globus Medical have a partnership to introduce robotic navigation in spinal surgeries that started with the Oxford University Hospitals NHS Foundation Trust and the Walton Centre NHS Foundation Trust Liverpool⁸ in 2022.

We expect Globus Medical’s revenues to grow by mid to high single-digits percentage over the coming years. This is mainly based on the expected double-digit growth of its “Enabling Technologies” segment that includes the ExcelsiusGPS™ product suite. In addition, the successful post-merger integration of NuVasive is expected to allow for a steady margin expansion during the same period. With a focus on continuous innovation, Globus is exploring artificial intelligence and advanced navigation systems to refine surgical techniques further.

The future

The next frontier in robotic surgery could be telesurgery—where surgeons operate remotely on patients in different locations. The first telesurgery took place in 2001, when a surgical team in New York used the ZEUS robotic system to perform surgery on a patient in France⁹.

Future advancements in augmented reality (AR) and virtual reality (VR) could enhance success by providing real-time overlays of medical imaging and anatomical structures for greater precision¹⁰. While a number of pre-clinical testing surgeries have been conducted on live humans and animals¹¹, challenges such as data latency, cybersecurity, data privacy and the danger of technical malfunction still need to be addressed before these futuristic technologies become routine in healthcare settings.

The robotic arm retracts as the procedure concludes, the monitors dim. Yet, the future of the operating room is far from silent—it hums with the promise of what human and technological collaborations can achieve.

¹ https://www.hospitalmanagement.net/features/feature634/
² https://boneandjoint.org.uk/article/10.1302/0301-620x.93b10.27418
³ https://pmc.ncbi.nlm.nih.gov/articles/PMC8657248/
⁴ https://www.treatingpain.com/news-updates/2019/july/5-surprising-facts-about-the-spine-you-never-kne/
⁵ https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)78342-2/fulltext
⁶ https://www.theguardian.com/society/2018/jul/04/robots-nhs-surgeons-keyhole-surgery-versius
https://www.theguardian.com/science/2023/jun/18/robot-surgeons-provide-many-benefits-but-how-autonomous-should-they-be
⁷ https://www.surgicalroboticstechnology.com/news/globus-medical-celebrates-20000-procedures-with-excelsiusgps/
⁸ https://www.spinalsurgerynews.com/2022/11/globus-medical-partners-with-the-uks-nhs-to-provide-hospitals-with-surgical-robotic-navigation-technology/110370
⁹ https://pmc.ncbi.nlm.nih.gov/articles/PMC6067812/
¹⁰ https://sloanmedical.com/how-9-breakthrough-technologies-are-shaping-the-future-of-surgery/
¹¹ https://link.springer.com/article/10.1007/s11701-024-01984-w

Foresight Group LLP completed an acquisition of the trade and assets of WHEB Asset Management LLP (WHEB). By way of Novation, Foresight Group LLP now acts as investment manager. Foresight Group LLP uses the trading names WHEB and WHEB Asset Management.

Foresight Group LLP and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 198020 and has its registered office at The Shard, 32 London Bridge Street, London, SE1 9SG. FundRock Partners Limited (formerly Fund Partners Limited) remains the Authorised Corporate Director of the Funds and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 469278 and has its registered office at Hamilton Centre, Rodney Way, Chelmsford, England, CM1 3BY.

Important Notices:

Risks include: the price of shares (“Shares”) in FP WHEB Sustainability Impact Fund, WHEB Sustainable Impact Fund or WHEB Environmental Impact Fund may increase or decrease and you may not get back the amount originally invested, for reasons including adverse market and foreign exchange rate movements. Past performance does not predict future returns. The Fund invests in equities and is exposed to price fluctuations in the equity markets, and focuses on investments in mid-sized companies in certain sectors so its performance may not correlate closely with the MSCI World Index (the benchmark). For full risks, please see fund prospectus on www.whebgroup.com

General: This information, its contents and any related communication (altogether, the “Information”) is issued by WHEB Asset Management LLP (“WHEB Asset Management”). It is intended for information purposes only and does not constitute or form part of any offer or invitation to buy or sell any security including any shares in the FP WHEB Sustainability Impact Fund or WHEB Sustainable Impact Fund, including in the United States. It should not be relied upon to make an investment decision in relation to Shares in the FP WHEB Sustainability Impact Fund or WHEB Sustainable Impact Fund or otherwise; any such investment decision should be made only on the basis of the Fund scheme documents and appropriate professional advice. This Information does not constitute advice of any kind, investment research or a research recommendation, is in summary form and is subject to change without notice. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming shares. WHEB Asset Management has exercised reasonable care in preparing this Information including using reliable sources, however, makes no representation or warranty relating to its accuracy, reliability or completeness or whether any future event may or may not occur. This Information is only made available to recipients who may lawfully receive it in accordance with applicable laws, regulations and rules and binding guidance of regulators. WHEB Asset Management LLP is registered in England and Wales with number OC 341489 and has its registered office at 7 Cavendish Square, London, W1G 0PE. WHEB Asset Management LLP is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 496413.

FP WHEB Sustainability Impact Fund

FundRock Partners Limited (formerly Fund Partners Limited) is the Authorised Corporate Director of the Fund and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 469278 and has its registered office at 6th Floor Bastion House, 140 London Wall, London, EC2Y 5DN. The state of the origin of the Fund is England and Wales. The Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, 8024 Zurich . The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the Representative in Switzerland.

WHEB Sustainable Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, 8024 Zurich. The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the representative in Switzerland. The state of the origin of the Fund is Ireland. The Fund is registered for distribution to professional investors in Austria, France, Germany, Italy, Luxembourg, Norway, Singapore, Sweden and the United Kingdom, and is registered for offering to retail investors in Switzerland, Denmark and the Netherlands. The Fund is also available for professional investors in Belgium and Hong Kong. It is not available to investors domiciled in the United States.

WHEB Environmental Impact Fund

The MSCI information may only be used for your internal use, may not be reproduced or re-dissseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).

How to invest

Join our mailing list